Brought to you by 
Sention licenses compounds from Merck
25 Jan 2005
Executive Summary
Sention Inc. (develops treatments for cognitive impairment and CNS disorders) has exclusively licensed from Merck & Co. Inc. a group of compounds called metabotropic glutamate receptor (mGluR) antagonists to use in the development of potential therapeutics for Fragile X mental retardation.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sention licenses compounds from Merck
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice